Concepedia

Adam R. Looker

AR

8

Publications

151

Citations

8

H-Index

2006

Active since

Affiliations

Vertex Pharmaceuticals (United States)(Current)

Takeda (United States)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Janssen (Belgium)

AbbVie (United States)

Adam R. Looker is an author at Vertex Pharmaceuticals (United States) specializing in bioanalysis, engineering, and medicine.

ORCID

Top concepts

Publications per year

2006–2019

8

Publications

8

A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategies

Chris Barber, Vincent Antonucci, Jens-Christoph Baumann et al. · Regulatory Toxicology and Pharmacology · 2017 · 33 citations

, , +8

Risk Assessment of Potentially Genotoxic Impurities within the Framework of Quality by Design

Adam R. Looker, Michael P. Ryan, Bobbianna J. Neubert-Langille et al. · Organic Process Research & Development · 2010 · 27 citations

, , +25

New Semi-Automated Computer-Based System for Assessing the Purge of Mutagenic Impurities

Michael J. Burns, Martin A. Ott, Andrew Teasdale et al. · Organic Process Research & Development · 2019 · 23 citations · Full text

Development and Manufacture of the Inosine Monophosphate Dehydrogenase Inhibitor Merimepodib, VX-497

Adam R. Looker, Benjamin J. Littler, Todd A. Blythe et al. · Organic Process Research & Development · 2008 · 18 citations

, , +15

Understanding the degradation pathway of a poorly water-soluble drug formulated in PEG-400

Jianmei Kochling, Christopher R. Young, Adam R. Looker et al. · Journal of Pharmaceutical and Biomedical Analysis · 2006 · 17 citations

, , +10

Rows per page

1–5 of 8